Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Assets (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Current Assets for 9 consecutive years, with $150.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 56.04% to $150.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.9 million through Dec 2025, down 56.04% year-over-year, with the annual reading at $150.9 million for FY2025, 56.04% down from the prior year.
  • Current Assets hit $150.9 million in Q4 2025 for Sutro Biopharma, down from $182.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $443.5 million in Q2 2024 to a low of $150.9 million in Q4 2025.
  • Historically, Current Assets has averaged $309.5 million across 5 years, with a median of $317.8 million in 2022.
  • Biggest five-year swings in Current Assets: soared 108.7% in 2021 and later tumbled 56.04% in 2025.
  • Year by year, Current Assets stood at $218.5 million in 2021, then surged by 61.61% to $353.2 million in 2022, then increased by 19.37% to $421.5 million in 2023, then fell by 18.56% to $343.3 million in 2024, then plummeted by 56.04% to $150.9 million in 2025.
  • Business Quant data shows Current Assets for STRO at $150.9 million in Q4 2025, $182.1 million in Q3 2025, and $231.6 million in Q2 2025.